Aero Therapeutics selected for JLABS @ San Diego

November 2, 2020

 

San Diego, CA - Aero Therapeutics Inc is pleased to announce that in January 2021 it will begin its residency at Johnson & Johnson (NYSE: JNJ) Innovation – JLABS @ San Diego.

 

In January 2012, San Diego became home to the flagship JLABS incubator site, launched by Johnson & Johnson (J&J) at its Janssen West Coast Research Center. Located in the heart of the Torrey Pines Mesa alongside world-class research institutes, JLABS @ San Diego is home to over 60 resident biotech startup companies, and has over 70 alumni companies within its network.

 

JLABS is a global network of open innovation ecosystems, enabling and empowering innovators across a broad healthcare spectrum including pharmaceutical, medical device, consumer and health tech sectors to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. JLABS is a “no-strings-attached” arrangement. There is no first look, no first right of refusal and no equity assigned to J&J or Janssen. This allows resident companies to maintain complete entrepreneurial freedom as they focus on scientific innovation.

 

“Johnson and Johnson is an incredibly knowledgeable company devoted to tackling the same challenges in global health that we are – in particular: addressing urgent unmet medical needs of neglected patients in extremely low resource settings both here and abroad. J&J’s practical experience and credo really resonated with us and we are very excited to begin our journey as a startup company within their incubator. Also, where better to do this than right here in San Diego – a city with such a robust ecosystem for medical device innovation.” said Jamison Langguth, CEO of Aero Therapeutics.

 

Every breath matters.

 

Aero Therapeutics is an early stage medical device company. Aero’s first device is a self-sterilizing high-flow respirator designed for extremely low resource settings. Prior to the pandemic, respiratory distress was responsible for 3.2% of all neonatal deaths in America, as well as affecting over 200K adult Americans per year. 1 out of 10 babies are born premature in America; the more premature the birth the more likely the newborn will need respiratory support. Despite advances in mechanical support and evolving concomitant surfactant therapies, neonatal respiratory distress (NRDS) remains lethal worldwide.

© 2020 by Aero Therapeutics